Comparison
Tirzepatide vs Retatrutide
Side-by-side attributes from our library comparison data. Read each peptide leaf for dosing math, regulatory status, and citations.
Tirzepatide vs. Retatrutide
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 + GIP + Glucagon triple agonist |
| Peak Weight Loss | 22.5% (SURMOUNT-1) | 28.7%+ (TRIUMPH Phase 2/3 data) |
| FDA Status | Approved (Mounjaro® / Zepbound®) | Phase 3 (not yet approved) |
| Availability | Branded + compounded | Compounded only (investigational) |
| Safety Track Record | Extensive Phase 3 + real-world data | Phase 3 data emerging |
Verdict: Retatrutide shows superior weight loss in Phase 3 data via its triple agonist mechanism, but remains investigational. Tirzepatide is the FDA-approved gold standard for proven maximum weight loss as of 2026.